The patient at the center of this current case was treated with pembrolizumab, a PD-1 checkpoint inhibitor. A drug screen performed on a panel of compounds found just one drug agent that elicited high sensitivity to the PDCLs, which crossed the blood—brain barrier; however, the drug was experimental and was not readily available to the patient.
All rights reserved This article has been cited by other articles in PMC. However, in this particular case the overlapping mutational landscape shared the same subclonal lineage as indicated by the consensus phylogenetic tree and two-dimensional analysis of the tumors Fig.
Cells were treated with five different concentrations 0.
Taken together, both p16 and MGMT genes have been considered as potentially useful candidate biomarkers for lung cancer treatment and early detection. In spite of extensive studies, pathogenic pathways to lung cancer in both smokers and never-smokers remain poorly understood.
No significant difference in the number of pack-years was found among male and female smokers. Network analysis revealed more than interconnected pathways affected by mutations from identified driver genes from the patient genome.